<DOC>
	<DOCNO>NCT00956410</DOCNO>
	<brief_summary>This study evaluate safety tolerability repeat subcutaneous injection CAD106 patient Alzheimer 's disease .</brief_summary>
	<brief_title>To Investigate Safety Tolerability Repeated Subcutaneous Injections CAD106 Alzheimer 's Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients complete Core study significant safety concern Diagnosis neurodegenerative disease and/or psychiatric disorder ( exception successfully treat depression ) . Diagnosis presence active , uncontrolled seizure disorder and/or cerebrovascular disease . diagnosis presence active autoimmune and/or acute chronic inflammation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Neurodegenerative disease</keyword>
	<keyword>Vaccine</keyword>
</DOC>